Anti-interleukin-1 alpha antibody MABp1 improves outcomes significantly over placebo

da Salute H24 — 2 luglio 2016 alle 17:12


A novel anti-interleukin 1-alpha antibody has shown a significant impact on symptoms, and a high level of safety and tolerability in patients with advanced colorectal cancer, according to phase III data (1) presented at the European Society for Medical Oncology’s 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. Continua »

AntonioCaperna

Scrivi un commento